November 2, 2026 · Mayo Clinic proceedings · DOI: 10.1016/j.mayocp.2026.08.017

Efficacy and Safety of Evogliptin in Mild to Moderate Calcific Aortic Valve Stenosis: The EVOID-AS Trial Rationale and Study Design.

Listen to this summary

The EVOID-AS trial asks whether evogliptin, a dipeptidyl peptidase-4 inhibitor, can slow aortic valve calcification and hemodynamic progression in patients with mild to moderate calcific aortic stenosis, a condition with no proven medical therapy. The authors describe a double-blind, placebo-controlled, randomized design in which 580 patients will receive evogliptin 10 mg or placebo daily for 2 years, with the primary endpoint being change in valve calcium score on cardiac CT. Secondary endpoints include echocardiographic progression of stenosis severity, time to aortic valve intervention, and treatment-emergent adverse events.

Ratnasari Padang, Roberto Hodara, M Fuad Jan, Renuka Jain, Alexander Postalian, Bryan M Zweig, Tasneem Z Naqvi, Robert A Levine, Jacob P Dal-Bianco, Edgar Argulian, Gregg S Pressman, Partho P Sengupta, Amr E Abbas, Wayne Cheng, Ankitkumar K Patel, Nicole M Bhave, Eugene S Chung, Carlos E Sanchecirf, Trace C Barrett, Smadar Kort, Jina Sohn, Peter Pollak, Mays T Ali, Scott Chadderdon, Qiong Zhao, Edward Gill, Fredy El Sakr, Naveen L Pereira, Adrian Vella, Phillip J Schulte, Kent R Bailey, Jae-Kwan Song, Jae K Oh

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play